This information applies
only to treatment of patients with an acute
porphyria (AIP, HCP, VP).
Evidence
on safety of drugs is drawn from three main
sources:
Clinical reports
Experimental systems ( e.g. chick
embryo hepatocyte culture)
Drug metabolism data
Combinations of drugs plus other factors (stress,
infection, malnutrition) may increase the
risk of an acute attack.
No drug
should be withheld if it is judged essential
for optimum treatment of a life-threatening
condition (e.g. chemotherapy for cancer).
Response
to drugs in patients with an acute porphyria
is extremely variable and individuals may
be encountered who have used an unsafe drug
without adverse effect.
| 
Print
